Items where Author is "Spelman, T."

Article

(2021) Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. E783-E797. ISSN 0028-3878

(2019) Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. pp. 458-468. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2017) Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal. pp. 266-276. ISSN 1352-4585

(2017) Contribution of inflammation to disability accrual in primary progressive multiple sclerosis. Multiple Sclerosis Journal. pp. 399-401. ISSN 1352-4585

(2017) Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years. Multiple Sclerosis Journal. pp. 361-363. ISSN 1352-4585

(2017) Prognostic Indicators in Pediatric Clinically Isolated Syndrome. Annals of Neurology. pp. 729-739. ISSN 0364-5134

(2017) Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 71-73. ISSN 1352-4585

(2017) Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. pp. 2426-2443. ISSN 0006-8950

(2017) The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. Multiple Sclerosis Journal. pp. 32-34. ISSN 1352-4585

(2016) Early disease modifying treatment delays disability accumulation in patients with pediatric onset clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal. pp. 62-63. ISSN 1352-4585

(2016) Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 1343-1349. ISSN 0022-3050

(2016) Individual response to disease modifying therapies: a global observational cohort study. Multiple Sclerosis Journal. pp. 358-360. ISSN 1352-4585

(2015) BREMSO: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology. pp. 981-989. ISSN 1351-5101